NYSE$OGN
Organon & Co. · Q4 2023 earnings
Q4 2023 earnings · · Investor relations
Briefing
Organon's Q4 2023 performance showcased revenue growth driven by Women's Health and Biosimilars, alongside improved profitability.
Organon reported an 8% increase in total revenue to $1,598 million for Q4 2023. The company's growth was primarily fueled by strong performances in Women's Health and Biosimilars segments. Net income increased significantly to $546 million, and adjusted EBITDA margin improved to 28.1%.
- Total revenue increased by 8% to $1,598 million compared to Q4 2022.
- Women's Health revenue grew by 7%, driven by fertility products and oral contraceptives.
- Biosimilars revenue increased by 49%, led by Ontruzant and Renflexis.
- Net income rose to $546 million, or $2.13 per diluted share, compared to $108 million, or $0.42 per diluted share, in Q4 2022.
Headline financials
Revenue & EPS history
Organon · Revenue · Quarterly
$1.6B
Revenue by segment
Organon · $1.52B total across 4 segments · Q3 2023
- Established Brands$959M—63.1%
- Women's Health$376M—24.8%
- Biosimilars$144M—9.5%
- Other$40M—2.6%
Forward guidance
Organon expects low-single-digit constant currency revenue growth and stable to improving Adjusted EBITDA margin for full year 2024.
Tailwinds
- Expects constant currency revenue growth in the low-single-digit range.
- Expects stable to improving Adjusted EBITDA margin.
- Achieve stable to improving Adjusted EBITDA margin through operating expense management.
- Priorities are to deliver their third year of constant currency revenue growth
- Well positioned at the forefront of women's health effort.
Headwinds
- Unable to reasonably predict certain items contained in the GAAP measures.
- Such items include acquisition related expenses.
- Such items include restructuring and related expenses
- Such items include stock-based compensation
- Such items include the ultimate outcome of legal proceedings
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2023
-0.9%
Avg return
Earnings day
-1.6%
Avg return
5 days after
-4.8%
Avg return
30 days after
40%
10 / 25 earnings
Positive
+14.4%
Q4 2023
Best reaction
-26.9%
Q1 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -0.6% | +0.1% | +0.1% | |
| Q4 2025 | -8.2% | -5.3% | -17.4% | |
| Q3 2025 | +14.0% | +11.1% | +5.9% | |
| Q1 2025 | -26.9% | -29.4% | -28.7% | |
| Q4 2024 | +11.0% | +5.3% | +4.1% | |
| Q3 2024 | +0.8% | -8.2% | -11.5% | |
| Q2 2024 | -5.6% | -0.2% | +5.8% | |
| Q1 2024 | +4.1% | +8.3% | +13.3% | |
| Q4 2023 | +14.4% | +13.0% | +11.7% | |
| Q3 2023 | -9.2% | -15.3% | -21.5% | |
| Q2 2023 | +6.2% | +6.2% | -10.7% | |
| Q1 2023 | -7.1% | -12.4% | -18.5% | |
| Q4 2022 | -11.1% | -7.6% | -25.9% | |
| Q3 2022 | -6.1% | -9.1% | +3.0% | |
| Q2 2022 | -3.3% | -3.6% | -12.5% | |
| Q1 2022 | +4.8% | +4.7% | +12.0% | |
| Q4 2019 | +0.8% | -0.3% | -4.9% | |
| Q4 2021 | -0.7% | -1.0% | -3.5% | |
| Q3 2020 | -3.9% | -5.1% | -17.2% | |
| Q3 2021 | -8.0% | -8.4% | -21.5% | |
| Q2 2020 | +3.4% | -2.9% | -1.4% | |
| Q2 2021 | +14.3% | +18.2% | +13.2% | |
| Q4 2020 | -1.5% | +0.7% | +1.6% | |
| Q1 2020 | -1.5% | +0.7% | +1.6% | |
| Q1 2021 | -1.5% | +0.7% | +1.6% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro